Literature DB >> 12720134

Immunophenotypic analysis of Waldenstrom's macroglobulinemia.

J F San Miguel1, M B Vidriales, E Ocio, G Mateo, F Sánchez-Guijo, M L Sánchez, L Escribano, A Bárez, M J Moro, J Hernández, C Aguilera, R Cuello, J García-Frade, R López, J Portero, A Orfao.   

Abstract

Immunophenotyping has become an essential tool for diagnosis of hematological malignancies. By contrast, for diagnosis of Waldenstrom's macroglobulinemia (WM) immunophenotyping is used only occasionally. From 150 patients with a IgM monoclonal gammopathy we have selected 60 cases with (1) morphological lymphoplasmocytoid bone marrow (BM) infiltration (>20%); (2) IgM paraprotein (>10g/L); and (3) absence of features of other lymphoma types. Immunophenotypic analysis was based on the use of the triple or quadruple monoclonal antibody (MoAb) combinations. To increase the sensitivity of the analysis of antigen expression, selected CD19(+)CD20(+) B cells were targeted. We have also explored the antigenic characteristics of both the plasma cell (PC) and mast cell (MC) compartments present in the BM from 15 WM patients. Clonal WM lymphocytes were characterized by the constant expression of pan-B markers (CD19, CD20, CD22, CD24) together with sIg, predominantly kappa (5:1, kappa:lambda ratio). A high proportion of cases (75%) were positive for FMC7 and CD25, but in contrast to hairy cell leukemia (HCL), these lymphocytes were always negative for CD103 and CD11c. CD10 antigen was also absent in all WM patients and less than one fifth of patients were positive for CD5 and CD23, while CD27, CD45RA, and BCL-2 were present in most malignant cells. In two cases, the coexistence of two different clones of B lymphocytes was identified, and in eight additional cases, intraclonal phenotypic heterogeneity was observed. As far as PCs are concerned, in most patients (85%) the number of PCs was within the normal range (median, 0.36%). The antigenic profile of these PCs differed from that observed in normal and myelomatous PC (CD38(++)CD19(++/-)CD56(-)CD45(++)CD20(+)). In three cases, PCs showed aberrant expression for CD5, CD22, or FMC7. Finally, the number of mast cells was significantly higher (0.058 +/- 0.13) as compared to normal BM (0.019 +/- 0.02) (P <.01), although they were immunophenotypically normal (CD117(+)CD2(-)CD25(-)). Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720134     DOI: 10.1053/sonc.2003.50074

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  23 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

Review 4.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

5.  What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Authors:  Steven P Treon; Jorge J Castillo
Journal:  Blood Adv       Date:  2017-11-28

Review 6.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

8.  TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

Authors:  Jennifer Shrimpton; Matthew A Care; Jonathan Carmichael; Kieran Walker; Paul Evans; Charlotte Evans; Ruth de Tute; Roger Owen; Reuben M Tooze; Gina M Doody
Journal:  Blood Adv       Date:  2020-06-23

Review 9.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

10.  CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

Authors:  Allen W Ho; Evdoxia Hatjiharissi; Bryan T Ciccarelli; Andrew R Branagan; Zachary R Hunter; Xavier Leleu; Olivier Tournilhac; Lian Xu; Kelly O'Connor; Robert J Manning; Daniel Ditzel Santos; Mariana Chemaly; Christopher J Patterson; Jacob D Soumerai; Nikhil C Munshi; Julie A McEarchern; Che-Leung Law; Iqbal S Grewal; Steven P Treon
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.